SCHEMBL3097165

SCHEMBL3097165

CCN(C(=O)C(Cc1cccc(-c2ccccc2)c1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 2/20 0.45
F2 P00734 3/20 0.44
KAT6A Q92794 2/20 0.43
CNR2 P34972 1/20 0.42
PLAT P00750 2/20 0.42
PLG P00747 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
BCL2L1 Q07817 1/20 0.41
MCL1 Q07820 1/20 0.41
LMNA P02545 1/20 0.40
GGPS1 O95749 1/20 0.40
PLAU P00749 2/20 0.40
CYP19A1 P11511 1/20 0.39
MME P08473 1/20 0.39
ACE P12821 1/20 0.39
CPA1 P15085 1/20 0.39
ACE2 Q9BYF1 1/20 0.39
NPY5R Q15761 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3100256 0.91 LARS1 (0.44) LARS1F2KAT6ACNR2PLAT
SCHEMBL3097333 0.90 LARS1 (0.45) LARS1F2CNR2PLATPLG
SCHEMBL3097466 0.86 KDM4E (0.47) LARS1F2KMT2AMCL1PLAU
SCHEMBL3100750 0.86 LARS1 (0.48) LARS1F2CNR2PLATPLG
SCHEMBL3083515 0.86 LARS1 (0.46) LARS1F2KAT6ACNR2MEN1
SCHEMBL3086148 0.86 LARS1 (0.46) LARS1F2KAT6ACNR2MEN1
SCHEMBL3093111 0.86 LARS1 (0.46) LARS1F2CNR2MEN1KMT2A
SCHEMBL3103912 0.86 LARS1 (0.46) LARS1F2CNR2MEN1KMT2A
SCHEMBL3086151 0.86 SLC16A3 (0.47) LARS1F2CNR2PLATPLG
SCHEMBL3100322 0.85 KDM4E (0.49) LARS1F2CNR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885F2 4128/4885KAT6A 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.